Regulators Recommended Approval for Pertuzumab Biosimilar
The CHMP has backed the authorization of Pebrilzo to treat HER2-positive breast cancer in the European Union.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you support the increased availability of biosimilar medications to reduce cancer treatment costs?
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the approval of Pebrilzo, a biosimilar of the drug pertuzumab. This development marks a step toward expanding treatment access for patients with HER2-positive breast cancer across various disease stages.
Why it matters
Biosimilars are designed to offer more affordable, high-quality alternatives to existing biological therapies. By supporting the authorization of this pertuzumab version, regulators aim to broaden the range of available options for managing HER2-positive breast cancer.
The CHMP based its positive opinion on a marketing authorization application for Pebrilzo, a 420 mg concentrate solution for infusion. The evaluation confirms the product is a biosimilar intended for use in HER2-positive breast cancer, though specific clinical trial data were not disclosed.
The players
CHMP
The Committee for Medicinal Products for Human Use is responsible for preparing opinions on questions concerning medicines for human use in the European Union.
Biocon Biologics
A pharmaceutical company specializing in the development and manufacturing of biosimilar products.
European Commission
The executive branch of the European Union that makes final decisions on drug marketing authorization based on CHMP recommendations.
The details
Biosimilars are developed to be highly similar to an existing, FDA- or EMA-approved biological medicine, ensuring they have no clinically meaningful differences in safety, purity, or potency. Pebrilzo functions by targeting the HER2 protein, which is overexpressed in some breast cancers, to inhibit cancer cell growth and survival. By following this established mechanism, the drug offers a therapeutic effect equivalent to the originator pertuzumab treatment.
Timeline
September 21, 2026: Biocon announced the positive CHMP opinion.
Health Landscape
This recommendation follows the established process of the EMA biosimilar authorization framework. It reflects a broader trend of expanding market options for monoclonal antibody treatments used in oncology.
If you or a loved one are undergoing treatment for HER2-positive breast cancer, the introduction of biosimilars may change the available options for therapy. It is worth discussing your current treatment plan and the potential role of biosimilar medications with your oncologist.
The takeaway
The regulatory support for this biosimilar highlights the increasing role of cost-effective alternatives in cancer care. Patients and caregivers should remain informed about new treatment options by keeping up to date with guidance from their primary oncology team.
What happens next
The European Commission will conduct a final review of the marketing authorization application to make a binding decision, followed by the future publication of the European Public Assessment Report on the EMA website.
Further reading
For more information on the current treatment options and care standards, visit the Cancer section.
Live Poll
Do you support the increased availability of biosimilar medications to reduce cancer treatment costs?
